Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Outcomes & treatment options for patients with AML who relapse after alloHSCT

Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, talks on the outcomes of patients with FLT3-mutated acute myeloid leukemia (AML) who relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT), sharing her excitement for the upcoming approval of FLT3 inhibitors in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.